{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:30:47Z","timestamp":1780097447687,"version":"3.54.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s12325-024-03017-2","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T09:11:28Z","timestamp":1732612288000},"page":"537-547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Our Experience in Treating Infantile Hemangioma: Prognostic Factors for Relapse After Propranolol Discontinuation"],"prefix":"10.1007","volume":"42","author":[{"given":"Hiba","family":"Zaaroura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afik","family":"Tibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Avitan-Hersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-2807","authenticated-orcid":false,"given":"Ziad","family":"Khamaysi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"3","key":"3017_CR1","doi-asserted-by":"publisher","first-page":"e14936","DOI":"10.1111\/dth.14936","volume":"34","author":"N Pam","year":"2021","unstructured":"Pam N, Kridin K, Khamaysi Z. Propranolol for infantile hemangioma: evaluating efficacy and predictors of response and rebound growth. Dermatol Ther. 2021;34(3):e14936.","journal-title":"Dermatol Ther"},{"issue":"2","key":"3017_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","volume":"25","author":"C Kilcline","year":"2008","unstructured":"Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol. 2008;25(2):168\u201373.","journal-title":"Pediatr Dermatol"},{"key":"3017_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-3475","author":"DP Krowchuk","year":"2019","unstructured":"Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical practice guideline for the management of infantile hemangiomas. Pediatrics. 2019. https:\/\/doi.org\/10.1542\/peds.2018-3475.","journal-title":"Pediatrics"},{"key":"3017_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13331","author":"K Kridin","year":"2020","unstructured":"Kridin K, Pam N, Bergman R, Khamaysi Z. Oral propranolol administration is effective for infantile hemangioma in late infancy: a retrospective cohort study. Dermatol Ther. 2020. https:\/\/doi.org\/10.1111\/dth.13331.","journal-title":"Dermatol Ther"},{"key":"3017_CR5","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.200","author":"AL Bruckner","year":"2003","unstructured":"Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003. https:\/\/doi.org\/10.1067\/mjd.2003.200.","journal-title":"J Am Acad Dermatol"},{"key":"3017_CR6","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2767","author":"LC Chang","year":"2008","unstructured":"Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008. https:\/\/doi.org\/10.1542\/peds.2007-2767.","journal-title":"Pediatrics"},{"key":"3017_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvs.2015.06.197","author":"C L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","unstructured":"L\u00e9aut\u00e9-Labr\u00e8ze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015. https:\/\/doi.org\/10.1016\/j.jvs.2015.06.197.","journal-title":"N Engl J Med"},{"key":"3017_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01644.x","author":"L Bagazgoitia","year":"2011","unstructured":"Bagazgoitia L, Hern\u00e1ndez-Mart\u00edn \u00c1, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol. 2011. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01644.x.","journal-title":"Pediatr Dermatol"},{"key":"3017_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12190","author":"N Shehata","year":"2013","unstructured":"Shehata N, Powell J, Dubois J, et al. Late rebound of infantile hemangioma after cessation of oral propranolol. Pediatr Dermatol. 2013. https:\/\/doi.org\/10.1111\/pde.12190.","journal-title":"Pediatr Dermatol"},{"key":"3017_CR10","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-1754","author":"SD Shah","year":"2016","unstructured":"Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy. Pediatrics. 2016. https:\/\/doi.org\/10.1542\/peds.2015-1754.","journal-title":"Pediatrics"},{"key":"3017_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.034","author":"L Wang","year":"2023","unstructured":"Wang L, Wang MMW, Zhou Z, et al. Exploration of the optimal time to discontinue propranolol treatment in infantile hemangiomas: a prospective study. J Am Acad Dermatol. 2023. https:\/\/doi.org\/10.1016\/j.jaad.2023.12.034.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3017_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.abd.2021.05.009","volume":"97","author":"LG Mariani","year":"2022","unstructured":"Mariani LG, Ferreira LM, Rovaris DL, Bonamigo RR, Kiszewski AE. Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae. An Bras Dermatol. 2022;97(1):37\u201344.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"3017_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.annder.2023.03.007","volume":"150","author":"C Mauguen","year":"2023","unstructured":"Mauguen C, Maruani A, Barbarot S, et al. Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: a case-control study using the 2014\u20132021 French ouest datahub. Ann Dermatol Venereol. 2023;150(3):189\u201394.","journal-title":"Ann Dermatol Venereol"},{"issue":"7","key":"3017_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1001\/jamaoto.2021.0454","volume":"147","author":"Y Ji","year":"2021","unstructured":"Ji Y, Chen S, Yang K, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial. JAMA Otolaryngol Neck Surg. 2021;147(7):599\u2013607. https:\/\/doi.org\/10.1001\/jamaoto.2021.0454.","journal-title":"JAMA Otolaryngol Neck Surg"},{"key":"3017_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01664.x","author":"A Chakkittakandiyil","year":"2012","unstructured":"Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2012. https:\/\/doi.org\/10.1111\/j.1525-1470.2011.01664.x.","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"3017_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s12098-023-04586-w","volume":"90","author":"VK Yenamandra","year":"2023","unstructured":"Yenamandra VK, Khute P, Yadav D, et al. Oral propranolol therapy for infantile hemangioma: long-term follow-up. Indian J Pediatr. 2023;90(9):937\u20139. https:\/\/doi.org\/10.1007\/s12098-023-04586-w.","journal-title":"Indian J Pediatr"},{"key":"3017_CR17","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5999\/aps.2018.00318","volume":"45","author":"J Kim","year":"2018","unstructured":"Kim J, Hong JW, Roh TS, Lee WJ. Oral propranolol therapy in 23 infants with infantile hemangioma. Arch Plast Surg. 2018;45:517\u201324.","journal-title":"Arch Plast Surg"},{"issue":"5","key":"3017_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/1346-8138.14847","volume":"46","author":"SJ Chang","year":"2019","unstructured":"Chang SJ, Yu W, Gu Y, et al. Location of infantile hemangioma is a predictor of volumetric sequelae after involution. J Dermatol. 2019;46(5):371\u20135.","journal-title":"J Dermatol"},{"issue":"3","key":"3017_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoto.2013.6524","volume":"140","author":"JA Perkins","year":"2014","unstructured":"Perkins JA, Chen BS, Saltzman B, Manning SC, Parikh SR. Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. JAMA Otolaryngol Neck Surg. 2014;140(3):220\u20137. https:\/\/doi.org\/10.1001\/jamaoto.2013.6524.","journal-title":"JAMA Otolaryngol Neck Surg"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03017-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03017-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03017-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T11:03:53Z","timestamp":1738235033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03017-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03017-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"4 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiba Zaaroura, Afik Tibi, Emily Avitan-Hersh, and  Ziad\u00a0Khamaysi declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Because of the retrospective nature of the study, we did not obtain consent from the patients, but we did obtain consent to publish. The study was approved by the local institutional review board committee\u2014approval number 0624-23.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}